25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Aileron Therapeutics Inc
Buy, Hold or Sell?

Let's analyze Aileron Therapeutics Inc together

I guess you are interested in Aileron Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Aileron Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Aileron Therapeutics Inc

I send you an email if I find something interesting about Aileron Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Aileron Therapeutics Inc (30 sec.)










1.2. What can you expect buying and holding a share of Aileron Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$4.66
Expected worth in 1 year
$8.73
How sure are you?
22.9%

+ What do you gain per year?

Total Gains per Share
$4.07
Return On Investment
142.9%

For what price can you sell your share?

Current Price per Share
$2.85
Expected price per share
$1.12 - $4.12
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Aileron Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)
$2.85
Intrinsic Value Per Share
$-18.12 - $-21.34
Total Value Per Share
$-13.45 - $-16.68

2.2. Growth of Aileron Therapeutics Inc (5 min.)




Is Aileron Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$101m$17m$35.5m67.5%

How much money is Aileron Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$6.3m-$4.2m-$2m-32.7%
Net Profit Margin-1,327.1%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Aileron Therapeutics Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#353 / 950

Most Revenue
#719 / 950

Most Profit
#469 / 950

Most Efficient
#735 / 950
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Aileron Therapeutics Inc?

Welcome investor! Aileron Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Aileron Therapeutics Inc.

First you should know what it really means to hold a share of Aileron Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Aileron Therapeutics Inc is $2.85. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Aileron Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Aileron Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $4.66. Based on the TTM, the Book Value Change Per Share is $1.02 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.18 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Aileron Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.41-14.5%-0.29-10.2%-0.17-5.9%-0.27-9.6%-0.32-11.2%
Usd Book Value Change Per Share0.4515.7%1.0235.7%-0.18-6.4%0.165.8%0.134.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.4515.7%1.0235.7%-0.18-6.4%0.165.8%0.134.7%
Usd Price Per Share2.77-3.49-1.40-1.48-2.42-
Price to Earnings Ratio-1.68--3.37--3.05--1.74--2.16-
Price-to-Total Gains Ratio6.20--7.01--11.44--8.51--8.28-
Price to Book Ratio0.59-3.67-1.97-1.63-1.57-
Price-to-Total Gains Ratio6.20--7.01--11.44--8.51--8.28-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.85
Number of shares350
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share1.020.16
Usd Total Gains Per Share1.020.16
Gains per Quarter (350 shares)356.3257.38
Gains per Year (350 shares)1,425.26229.51
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10142514150230220
20285128400459450
30427642650689680
40570156900918910
5071267115011481140
6085528540013771370
7099779965016071600
801140211390018361830
901282712815020662060
1001425314240022952290

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.035.00.00.0%0.035.00.00.0%
Book Value Change Per Share2.02.00.050.0%2.010.00.016.7%4.016.00.020.0%8.023.04.022.9%8.023.04.022.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.035.00.0%0.00.035.00.0%
Total Gains per Share2.02.00.050.0%2.010.00.016.7%4.016.00.020.0%8.023.04.022.9%8.023.04.022.9%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Aileron Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.4471.018-56%-0.183+141%0.164+173%0.133+236%
Book Value Per Share--4.6632.428+92%0.789+491%1.489+213%0.938+397%
Current Ratio--4.6914.888-4%7.504-37%7.211-35%6.137-24%
Debt To Asset Ratio--0.0770.304-75%0.143-47%0.232-67%0.671-89%
Debt To Equity Ratio--0.0833.677-98%0.169-51%0.996-92%0.740-89%
Dividend Per Share----0%-0%-0%-0%
Eps---0.413-0.291-29%-0.167-59%-0.273-34%-0.320-23%
Free Cash Flow Per Share---0.387-0.296-23%-0.221-43%-0.268-31%-0.275-29%
Free Cash Flow To Equity Per Share--0.4560.278+64%-0.221+149%0.012+3721%0.027+1583%
Gross Profit Margin--1.0001.0020%1.000+0%1.000+0%1.000+0%
Intrinsic Value_10Y_max---21.343--------
Intrinsic Value_10Y_min---18.117--------
Intrinsic Value_1Y_max---1.257--------
Intrinsic Value_1Y_min---1.234--------
Intrinsic Value_3Y_max---4.448--------
Intrinsic Value_3Y_min---4.233--------
Intrinsic Value_5Y_max---8.450--------
Intrinsic Value_5Y_min---7.785--------
Market Cap61747530.000+3%60014266.00075660223.470-21%30368410.215+98%32169054.853+87%52354291.459+15%
Net Profit Margin----13.2710%-0%-2.6540%-1.5170%
Operating Margin----13.5520%-0%-2.7100%-1.5490%
Operating Ratio---13.552-100%-0%2.710-100%1.549-100%
Pb Ratio0.611+3%0.5943.675-84%1.967-70%1.628-64%1.571-62%
Pe Ratio-1.726-3%-1.678-3.371+101%-3.046+82%-1.744+4%-2.157+29%
Price Per Share2.850+3%2.7703.492-21%1.402+98%1.485+87%2.416+15%
Price To Free Cash Flow Ratio-1.840-3%-1.788-3.803+113%-1.906+7%-1.640-8%-2.541+42%
Price To Total Gains Ratio6.374+3%6.195-7.015+213%-11.440+285%-8.510+237%-8.279+234%
Quick Ratio--4.4443.635+22%10.479-58%10.640-58%9.137-51%
Return On Assets---0.082-0.091+12%-0.205+151%-0.181+122%-0.297+264%
Return On Equity---0.089-0.349+294%-0.242+174%-0.297+235%-0.466+426%
Total Gains Per Share--0.4471.018-56%-0.183+141%0.164+173%0.133+236%
Usd Book Value--101021000.00052610000.000+92%17096500.000+491%32251150.000+213%20317257.143+397%
Usd Book Value Change Per Share--0.4471.018-56%-0.183+141%0.164+173%0.133+236%
Usd Book Value Per Share--4.6632.428+92%0.789+491%1.489+213%0.938+397%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.413-0.291-29%-0.167-59%-0.273-34%-0.320-23%
Usd Free Cash Flow---8389000.000-6422750.000-23%-4789250.000-43%-5801303.297-31%-5947430.455-29%
Usd Free Cash Flow Per Share---0.387-0.296-23%-0.221-43%-0.268-31%-0.275-29%
Usd Free Cash Flow To Equity Per Share--0.4560.278+64%-0.221+149%0.012+3721%0.027+1583%
Usd Market Cap61747530.000+3%60014266.00075660223.470-21%30368410.215+98%32169054.853+87%52354291.459+15%
Usd Price Per Share2.850+3%2.7703.492-21%1.402+98%1.485+87%2.416+15%
Usd Profit---8942000.000-6305250.000-29%-4244750.000-53%-6043550.000-32%-6276714.286-30%
Usd Revenue---33500.000-100%-0%6700.000-100%3828.571-100%
Usd Total Gains Per Share--0.4471.018-56%-0.183+141%0.164+173%0.133+236%
 EOD+6 -2MRQTTM+14 -18YOY+19 -115Y+21 -1110Y+20 -12

3.3 Fundamental Score

Let's check the fundamental score of Aileron Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.726
Price to Book Ratio (EOD)Between0-10.611
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than14.444
Current Ratio (MRQ)Greater than14.691
Debt to Asset Ratio (MRQ)Less than10.077
Debt to Equity Ratio (MRQ)Less than10.083
Return on Equity (MRQ)Greater than0.15-0.089
Return on Assets (MRQ)Greater than0.05-0.082
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Aileron Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.341
Ma 20Greater thanMa 503.176
Ma 50Greater thanMa 1003.445
Ma 100Greater thanMa 2002.986
OpenGreater thanClose2.880
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Aileron Therapeutics Inc

Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.

Fundamental data was last updated by Penke on 2024-11-14 09:45:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Aileron Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Aileron Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Aileron Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-1,327.1%+1,327.1%
TTM-1,327.1%YOY--1,327.1%
TTM-1,327.1%5Y-265.4%-1,061.6%
5Y-265.4%10Y-151.7%-113.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--112.2%+112.2%
TTM-1,327.1%-221.4%-1,105.7%
YOY--210.0%+210.0%
5Y-265.4%-342.2%+76.8%
10Y-151.7%-464.5%+312.8%
4.3.1.2. Return on Assets

Shows how efficient Aileron Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Aileron Therapeutics Inc to the Biotechnology industry mean.
  • -8.2% Return on Assets means that Aileron Therapeutics Inc generated $-0.08 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Aileron Therapeutics Inc:

  • The MRQ is -8.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -9.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8.2%TTM-9.1%+1.0%
TTM-9.1%YOY-20.5%+11.4%
TTM-9.1%5Y-18.1%+9.0%
5Y-18.1%10Y-29.7%+11.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.2%-11.3%+3.1%
TTM-9.1%-11.7%+2.6%
YOY-20.5%-11.3%-9.2%
5Y-18.1%-12.7%-5.4%
10Y-29.7%-14.1%-15.6%
4.3.1.3. Return on Equity

Shows how efficient Aileron Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Aileron Therapeutics Inc to the Biotechnology industry mean.
  • -8.9% Return on Equity means Aileron Therapeutics Inc generated $-0.09 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Aileron Therapeutics Inc:

  • The MRQ is -8.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -34.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8.9%TTM-34.9%+26.0%
TTM-34.9%YOY-24.2%-10.6%
TTM-34.9%5Y-29.7%-5.2%
5Y-29.7%10Y-46.6%+16.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.9%-14.2%+5.3%
TTM-34.9%-15.9%-19.0%
YOY-24.2%-14.3%-9.9%
5Y-29.7%-18.5%-11.2%
10Y-46.6%-19.3%-27.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Aileron Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Aileron Therapeutics Inc is operating .

  • Measures how much profit Aileron Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Aileron Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Aileron Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-1,355.2%+1,355.2%
TTM-1,355.2%YOY--1,355.2%
TTM-1,355.2%5Y-271.0%-1,084.2%
5Y-271.0%10Y-154.9%-116.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--222.9%+222.9%
TTM-1,355.2%-310.7%-1,044.5%
YOY--223.5%+223.5%
5Y-271.0%-387.1%+116.1%
10Y-154.9%-498.5%+343.6%
4.3.2.2. Operating Ratio

Measures how efficient Aileron Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Aileron Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM13.552-13.552
TTM13.552YOY-+13.552
TTM13.5525Y2.710+10.842
5Y2.71010Y1.549+1.162
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.465-2.465
TTM13.5523.253+10.299
YOY-3.298-3.298
5Y2.7104.788-2.078
10Y1.5496.494-4.945
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Aileron Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Aileron Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.69 means the company has $4.69 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Aileron Therapeutics Inc:

  • The MRQ is 4.691. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.888. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.691TTM4.888-0.197
TTM4.888YOY7.504-2.616
TTM4.8885Y7.211-2.323
5Y7.21110Y6.137+1.074
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.6913.637+1.054
TTM4.8883.890+0.998
YOY7.5044.666+2.838
5Y7.2115.953+1.258
10Y6.1376.277-0.140
4.4.3.2. Quick Ratio

Measures if Aileron Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Aileron Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 4.44 means the company can pay off $4.44 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Aileron Therapeutics Inc:

  • The MRQ is 4.444. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.635. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.444TTM3.635+0.810
TTM3.635YOY10.479-6.845
TTM3.6355Y10.640-7.005
5Y10.64010Y9.137+1.503
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.4443.086+1.358
TTM3.6353.451+0.184
YOY10.4794.456+6.023
5Y10.6405.931+4.709
10Y9.1376.436+2.701
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Aileron Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Aileron Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Aileron Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.08 means that Aileron Therapeutics Inc assets are financed with 7.7% credit (debt) and the remaining percentage (100% - 7.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Aileron Therapeutics Inc:

  • The MRQ is 0.077. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.304. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.077TTM0.304-0.228
TTM0.304YOY0.143+0.161
TTM0.3045Y0.232+0.072
5Y0.23210Y0.671-0.438
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0770.350-0.273
TTM0.3040.344-0.040
YOY0.1430.310-0.167
5Y0.2320.365-0.133
10Y0.6710.382+0.289
4.5.4.2. Debt to Equity Ratio

Measures if Aileron Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Aileron Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 8.3% means that company has $0.08 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Aileron Therapeutics Inc:

  • The MRQ is 0.083. The company is very able to pay all its debts with equity. +2
  • The TTM is 3.677. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ0.083TTM3.677-3.594
TTM3.677YOY0.169+3.507
TTM3.6775Y0.996+2.680
5Y0.99610Y0.740+0.257
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0830.394-0.311
TTM3.6770.432+3.245
YOY0.1690.380-0.211
5Y0.9960.451+0.545
10Y0.7400.490+0.250
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Aileron Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Aileron Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -1.68 means the investor is paying $-1.68 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Aileron Therapeutics Inc:

  • The EOD is -1.726. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.678. Based on the earnings, the company is expensive. -2
  • The TTM is -3.371. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.726MRQ-1.678-0.048
MRQ-1.678TTM-3.371+1.693
TTM-3.371YOY-3.046-0.325
TTM-3.3715Y-1.744-1.627
5Y-1.74410Y-2.157+0.413
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.726-2.303+0.577
MRQ-1.678-2.403+0.725
TTM-3.371-3.148-0.223
YOY-3.046-3.251+0.205
5Y-1.744-6.084+4.340
10Y-2.157-6.764+4.607
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Aileron Therapeutics Inc:

  • The EOD is -1.840. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.788. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.803. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.840MRQ-1.788-0.052
MRQ-1.788TTM-3.803+2.014
TTM-3.803YOY-1.906-1.897
TTM-3.8035Y-1.640-2.162
5Y-1.64010Y-2.541+0.901
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.840-3.042+1.202
MRQ-1.788-3.234+1.446
TTM-3.803-3.719-0.084
YOY-1.906-4.557+2.651
5Y-1.640-8.332+6.692
10Y-2.541-9.276+6.735
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Aileron Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.59 means the investor is paying $0.59 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Aileron Therapeutics Inc:

  • The EOD is 0.611. Based on the equity, the company is cheap. +2
  • The MRQ is 0.594. Based on the equity, the company is cheap. +2
  • The TTM is 3.675. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD0.611MRQ0.594+0.017
MRQ0.594TTM3.675-3.080
TTM3.675YOY1.967+1.708
TTM3.6755Y1.628+2.047
5Y1.62810Y1.571+0.057
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.6111.943-1.332
MRQ0.5942.051-1.457
TTM3.6752.356+1.319
YOY1.9672.454-0.487
5Y1.6283.714-2.086
10Y1.5714.378-2.807
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Aileron Therapeutics Inc.

4.8.1. Institutions holding Aileron Therapeutics Inc

Institutions are holding 28.445% of the shares of Aileron Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-06-30University Of Texas Investment Mgmt Co8.20570.96177782717778270
2024-06-30Nantahala Capital Management, LLC4.28660.0754928734673734264.2094
2024-06-30Alyeska Investment Group, L.P.2.49240.00865400005400000
2024-06-30Vanguard Group Inc2.336205061534658391155.5266
2024-06-30Cable Car Capital LLC1.93851.22574200004200000
2024-06-30Prosight Management, LP1.22310.21942650002650000
2024-06-30RIMA MANAGEMENT, LLC1.06570.022123089500
2024-06-30Geode Capital Management, LLC0.78670170447100688144.3369
2024-06-30Sigma Planning Corp0.58260.01111262255824085.666
2024-06-30Kepos Capital LP0.48930.11421060001060000
2024-06-30Royal Bank of Canada0.2780602412424167.3361
2024-06-30Gagnon Securities LLC0.17530.023737977300.0791
2024-06-30Warberg Asset Management LLC0.14470.013131354313540
2024-06-30BlackRock Inc0.1444031285312850
2024-06-30Blair William & Co0.12950.000228047-250-0.8835
2024-06-30Texas Capital Bank Wealth Management Services Inc0.12080.00752617100
2024-06-30Northern Trust Corp0.1189025763257630
2024-06-30Renaissance Technologies Corp0.11480.000124864-20200-44.8251
2024-06-30State Street Corp0.048010404104040
2024-06-30Tower Research Capital LLC0.01780.00023864184491.2871
Total 24.6992.68135351251+4511799+84.3%

4.9.2. Funds holding Aileron Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Vanguard Institutional Extnd Mkt Idx Tr1.93590.0014419427-86363-17.0749
2024-09-30Fidelity Extended Market Index0.5250.001113743-2257-1.9457
2024-10-31iShares Micro-Cap ETF0.21170.0214585700
2024-09-30Fidelity Total Market Index0.14750.00013195024275316.2866
2024-09-30Fidelity Series Total Market Index0.10170.00012203713870169.8298
2024-09-30Northern Trust Extended Eq Market Idx0.09750.0012113000
2024-09-30NT Ext Equity Mkt Idx Fd - L0.09750.0012113000
2024-09-30Vanguard U.S. Eq Idx £ Acc0.0590.000212774127740
2024-09-30Fidelity Nasdaq Composite Index0.04420.0002957900
2024-09-30Spartan Total Market Index Pool E0.03410.0001739600
2024-10-31State St US Extended Mkt Indx NL Cl C0.02650.0012574000
2024-09-30Spartan Extended Market Index Pool E0.01960.00044238127743.1273
2024-09-301290 VT Micro Cap K0.01540.0073332700
2024-09-30NT Ext Equity Mkt Idx Fd - NL0.01530.0002331400
2024-09-30NT Ext Eq Mkt Indx Fd DC Lending Tier 50.01510.001326150.1536
2024-09-30NT Ext Equity Mkt Idx Fd - DC - NL - T20.01230.0002267080.3005
2024-06-30SSgA U.S. Total Market Index Strategy0.01090.000123541939467.2289
2024-09-30Northern Trust Wilshire 50000.00610.0002131900
2024-10-31State St US Ttl Mkt Indx SL Cl I0.0018040000
2024-09-30Fidelity U.S. Equity Index Ins Trust0.00080.000117500
Total 3.37790.0368731821-34472-4.7%

5.3. Insider Transactions

Insiders are holding 0.65% of the shares of Aileron Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-06-17Of Texas/texas Am I UniversitySELL47073.25
2024-06-14Of Texas/texas Am I UniversitySELL19003.3
2024-06-12Of Texas/texas Am I UniversitySELL93423.25
2024-06-10Of Texas/texas Am I UniversitySELL95773.3
2024-06-07Of Texas/texas Am I UniversitySELL17403.26
2024-06-05Of Texas/texas Am I UniversitySELL62913.3
2024-05-01Of Texas/texas Am I UniversitySELL203154.21
2024-04-29Of Texas/texas Am I UniversitySELL107464.95
2023-12-15James Brian WindsorBUY2253.37
2023-11-20James Brian WindsorBUY50761.97
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets109,400
Total Liabilities8,379
Total Stockholder Equity101,021
 As reported
Total Liabilities 8,379
Total Stockholder Equity+ 101,021
Total Assets = 109,400

Assets

Total Assets109,400
Total Current Assets23,159
Long-term Assets86,241
Total Current Assets
Cash And Cash Equivalents 21,942
Other Current Assets 1,217
Total Current Assets  (as reported)23,159
Total Current Assets  (calculated)23,159
+/-0
Long-term Assets
Property Plant Equipment 2
Goodwill 6,330
Intangible Assets 79,200
Long-term Assets Other 709
Long-term Assets  (as reported)86,241
Long-term Assets  (calculated)86,241
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities4,937
Long-term Liabilities3,442
Total Stockholder Equity101,021
Total Current Liabilities
Accounts payable 782
Other Current Liabilities 4,155
Total Current Liabilities  (as reported)4,937
Total Current Liabilities  (calculated)4,937
+/-0
Long-term Liabilities
Long-term Liabilities Other 116
Long-term Liabilities  (as reported)3,442
Long-term Liabilities  (calculated)116
+/- 3,326
Total Stockholder Equity
Common Stock107
Retained Earnings -304,572
Other Stockholders Equity 360,503
Total Stockholder Equity (as reported)101,021
Total Stockholder Equity (calculated)56,038
+/- 44,983
Other
Capital Stock107
Cash and Short Term Investments 21,942
Common Stock Shares Outstanding 19,911
Liabilities and Stockholders Equity 109,400
Net Debt -21,942
Net Invested Capital 56,016
Net Working Capital 18,222



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
> Total Assets 
5,940
0
0
0
22,021
17,155
15,105
59,036
52,688
52,688
42,577
38,133
30,312
22,399
40,193
33,952
26,473
20,373
26,125
22,239
16,341
64,671
60,531
54,768
48,481
40,255
33,770
27,232
22,007
17,157
13,991
12,822
106,008
99,192
109,400
109,40099,192106,00812,82213,99117,15722,00727,23233,77040,25548,48154,76860,53164,67116,34122,23926,12520,37326,47333,95240,19322,39930,31238,13342,57752,68852,68859,03615,10517,15522,0210005,940
   > Total Current Assets 
4,026
0
0
0
21,073
15,982
11,992
58,117
51,840
51,840
37,206
30,053
21,775
14,389
32,559
26,497
19,550
13,687
19,670
15,974
16,326
64,324
60,152
54,423
48,177
39,993
33,550
27,054
21,873
17,105
13,952
12,793
18,266
12,764
23,159
23,15912,76418,26612,79313,95217,10521,87327,05433,55039,99348,17754,42360,15264,32416,32615,97419,67013,68719,55026,49732,55914,38921,77530,05337,20651,84051,84058,11711,99215,98221,0730004,026
       Cash And Cash Equivalents 
3,768
0
0
0
20,715
8,029
9,397
13,428
11,863
11,863
11,980
7,716
10,635
11,272
10,157
6,867
5,311
10,697
17,124
7,850
7,046
19,283
10,748
7,603
3,600
7,449
7,628
4,839
5,194
7,783
13,167
12,069
17,313
12,067
21,942
21,94212,06717,31312,06913,1677,7835,1944,8397,6287,4493,6007,60310,74819,2837,0467,85017,12410,6975,3116,86710,15711,27210,6357,71611,98011,86311,86313,4289,3978,02920,7150003,768
       Short-term Investments 
0
0
0
0
25
7,265
1,946
43,437
38,889
38,889
23,811
20,229
10,060
1,998
21,365
17,694
12,967
1,998
1,756
6,271
6,759
44,068
48,731
44,629
42,333
30,626
24,754
20,638
16,048
8,938
499
0
0
0
0
00004998,93816,04820,63824,75430,62642,33344,62948,73144,0686,7596,2711,7561,99812,96717,69421,3651,99810,06020,22923,81138,88938,88943,4371,9467,265250000
       Other Current Assets 
258
0
0
0
358
688
649
1,252
1,088
1,088
1,415
2,108
1,055
1,119
1,012
1,911
1,247
967
765
1,828
1,928
948
648
2,166
2,219
1,893
1,143
1,552
606
359
261
699
721
697
1,217
1,2176977216992613596061,5521,1431,8932,2192,1666489481,9281,8287659671,2471,9111,0121,1191,0552,1081,4151,0881,0881,252649688358000258
   > Long-term Assets 
0
0
0
0
948
1,173
3,113
919
848
848
5,371
8,080
8,537
8,010
7,634
7,455
6,923
6,686
6,455
6,265
15
347
379
345
304
262
220
178
134
52
39
29
87,742
86,428
86,241
86,24186,42887,742293952134178220262304345379347156,2656,4556,6866,9237,4557,6348,0108,5378,0805,3718488489193,1131,1739480000
       Property Plant Equipment 
351
0
0
0
107
123
109
111
154
154
4,123
6,832
7,290
6,941
6,764
6,585
6,355
6,118
5,887
5,697
15
326
355
321
280
238
196
154
110
52
39
29
19
6
2
2619293952110154196238280321355326155,6975,8876,1186,3556,5856,7646,9417,2906,8324,123154154111109123107000351
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,330
6,330
6,330
6,3306,3306,33000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
79,200
79,200
79,200
79,20079,20079,20000000000000000000000000000000000
       Long-term Assets Other 
0
0
0
0
841
1,050
3,004
808
694
694
1,248
1,248
1,247
1,069
870
870
568
568
568
568
0
21
24
24
24
24
24
24
24
0
0
0
53
892
709
70989253000242424242424242105685685685688708701,0691,2471,2481,2486946948083,0041,0508410000
> Total Liabilities 
2,578
0
0
0
133,827
2,875
135,883
5,023
4,891
4,891
9,709
12,102
10,712
9,552
10,209
11,136
10,425
10,604
9,471
9,781
4,179
3,252
4,401
4,659
4,577
4,146
5,151
4,536
3,384
2,884
1,197
1,624
99,121
7,858
8,379
8,3797,85899,1211,6241,1972,8843,3844,5365,1514,1464,5774,6594,4013,2524,1799,7819,47110,60410,42511,13610,2099,55210,71212,1029,7094,8914,8915,023135,8832,875133,8270002,578
   > Total Current Liabilities 
2,549
0
0
0
4,071
2,871
5,471
5,023
4,891
4,891
6,364
7,105
5,370
4,623
5,387
6,428
5,839
6,143
4,926
5,249
3,960
3,073
4,273
4,560
4,508
4,146
5,151
4,536
3,384
2,884
1,197
1,624
4,385
4,532
4,937
4,9374,5324,3851,6241,1972,8843,3844,5365,1514,1464,5084,5604,2733,0733,9605,2494,9266,1435,8396,4285,3874,6235,3707,1056,3644,8914,8915,0235,4712,8714,0710002,549
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
1,020
0
0
387
406
426
446
468
661
560
168
422
93
93
93
131
100
67
33
0
0
0
0
48
0
04800003367100131939393422168560661468446426406387001,0200000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
1,020
0
0
387
0
0
0
0
171
48
168
329
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000329168481710000387001,0200000000000
       Accounts payable 
641
0
0
0
1,971
1,035
2,212
1,650
4,891
1,600
1,583
2,994
1,731
858
1,719
2,349
1,452
1,088
993
1,002
1,596
560
1,016
1,035
1,210
1,023
1,741
945
1,720
458
136
484
1,190
2,156
782
7822,1561,1904841364581,7209451,7411,0231,2101,0351,0165601,5961,0029931,0881,4522,3491,7198581,7312,9941,5831,6004,8911,6502,2121,0351,971000641
       Other Current Liabilities 
1,908
0
0
0
2,100
1,836
3,259
3,373
3,291
3,291
4,781
4,111
3,639
289
362
343
352
281
227
279
2,196
2,091
3,164
3,432
3,205
2,992
3,310
3,524
1,631
2,426
1,061
1,140
206
2,376
4,155
4,1552,3762061,1401,0612,4261,6313,5243,3102,9923,2053,4323,1642,0912,1962792272813523433622893,6394,1114,7813,2913,2913,3733,2591,8362,1000001,908
   > Long-term Liabilities 
0
0
0
0
129,756
4
130,412
0
0
0
3,345
4,997
5,342
4,929
4,822
4,708
4,586
4,461
4,545
4,532
219
179
128
99
69
1,154
1,841
1,012
1,753
458
0
0
94,736
3,326
3,442
3,4423,32694,736004581,7531,0121,8411,15469991281792194,5324,5454,4614,5864,7084,8224,9295,3424,9973,345000130,4124129,7560000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
3,345
4,997
5,342
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000005,3424,9973,3450000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
-1,020
0
0
4,929
4,822
4,708
4,586
4,461
4,161
4,148
-168
-205
128
99
69
0
0
0
0
0
0
0
48
-48
0
0-484800000006999128-205-1684,1484,1614,4614,5864,7084,8224,92900-1,0200000000000
       Warrants
0
0
0
0
0
0
130,412
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000130,412000000
       Other Liabilities 
29
0
0
0
11
4
0
0
0
0
3,345
4,997
5,342
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,536
0
0
0
0
0
0
0
00000004,536000000000000005,3424,9973,345000041100029
> Total Stockholder Equity
3,362
0
0
0
-111,806
14,280
-120,778
54,013
47,797
47,797
32,868
26,031
19,600
12,847
29,984
22,816
16,048
9,769
16,654
12,458
12,162
61,419
56,130
50,109
43,904
36,109
28,619
22,696
18,623
14,273
12,794
11,198
6,887
91,334
101,021
101,02191,3346,88711,19812,79414,27318,62322,69628,61936,10943,90450,10956,13061,41912,16212,45816,6549,76916,04822,81629,98412,84719,60026,03132,86847,79747,79754,013-120,77814,280-111,8060003,362
   Common Stock
4
0
0
0
0
11
0
15
15
15
15
15
15
15
28
28
28
28
39
40
44
90
90
91
91
91
91
91
91
91
91
91
0
103
107
10710309191919191919191919090444039282828281515151515151501100004
   Retained Earnings Total Equity0000000-268,2380000-231,953-226,267-219,292-214,296-209,273-204,883-198,135-190,900-183,151-175,979-168,493-161,459-154,025-144,534-136,946-130,081-123,822000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-2,094
-2,116
0
-6
-1,979
-33
-12
-3
-5
-1,206
24
17
7
-1
-2
-1
-2
-7
6
1
-13
-75
-101
-98
-48
-10
-2
0
0
-63
-22
-22-6300-2-10-48-98-101-75-1316-7-2-1-2-171724-1,206-5-3-12-33-1,979-60-2,116-2,0940000
   Capital Surplus 
0
0
0
0
0
0
3,044
184,085
184,761
185,544
186,890
187,478
188,083
188,811
213,083
213,671
214,148
214,625
225,890
226,715
231,412
287,603
287,987
0
0
0
0
290,941
0
0
0
0
0
0
0
0000000290,9410000287,987287,603231,412226,715225,890214,625214,148213,671213,083188,811188,083187,478186,890185,544184,761184,0853,044000000
   Treasury Stock00000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
4,630
135,284
-127,368
125,049
-33
184,761
186,890
187,478
188,083
188,811
213,083
213,671
214,148
214,625
225,890
226,715
231,412
287,603
287,987
288,674
289,282
289,971
290,499
290,941
291,365
291,756
292,056
292,285
0
340,340
360,503
360,503340,3400292,285292,056291,756291,365290,941290,499289,971289,282288,674287,987287,603231,412226,715225,890214,625214,148213,671213,083188,811188,083187,478186,890184,761-33125,049-127,368135,2844,6300000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-119
Gross Profit-119-119
 
Operating Income (+$)
Gross Profit-119
Operating Expense-16,276
Operating Income-16,276-16,395
 
Operating Expense (+$)
Research Development3,991
Selling General Administrative11,357
Selling And Marketing Expenses119
Operating Expense16,27615,467
 
Net Interest Income (+$)
Interest Income442
Interest Expense-0
Other Finance Cost-0
Net Interest Income442
 
Pretax Income (+$)
Operating Income-16,276
Net Interest Income442
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-15,732-16,820
EBIT - interestExpense = -15,348
-14,804
-15,732
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-15,348-15,732
Earnings Before Interest and Taxes (EBITDA)-15,229
 
After tax Income (+$)
Income Before Tax-15,732
Tax Provision-0
Net Income From Continuing Ops-12,940-15,732
Net Income-15,732
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses16,276
Total Other Income/Expenses Net544-442
 

Technical Analysis of Aileron Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Aileron Therapeutics Inc. The general trend of Aileron Therapeutics Inc is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Aileron Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Aileron Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3.21 < 3.32 < 4.12.

The bearish price targets are: 2.33 > 1.61 > 1.12.

Tweet this
Aileron Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Aileron Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Aileron Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Aileron Therapeutics Inc. The current macd is -0.24400667.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Aileron Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Aileron Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Aileron Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Aileron Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAileron Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Aileron Therapeutics Inc. The current adx is 30.51.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Aileron Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Aileron Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Aileron Therapeutics Inc. The current sar is 2.341.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Aileron Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Aileron Therapeutics Inc. The current rsi is 43.34. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Aileron Therapeutics Inc Daily Relative Strength Index (RSI) ChartAileron Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Aileron Therapeutics Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Aileron Therapeutics Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Aileron Therapeutics Inc Daily Stochastic Oscillator ChartAileron Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Aileron Therapeutics Inc. The current cci is -43.1506958.

Aileron Therapeutics Inc Daily Commodity Channel Index (CCI) ChartAileron Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Aileron Therapeutics Inc. The current cmo is -8.20301129.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Aileron Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAileron Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Aileron Therapeutics Inc. The current willr is -63.40694006.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Aileron Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Aileron Therapeutics Inc Daily Williams %R ChartAileron Therapeutics Inc Daily Williams %R Chart
3rd party ad